Cytek Biosciences (CTKB) News Today $6.13 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Brown Capital Management LLC Has $52.59 Million Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)Brown Capital Management LLC cut its position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 16.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,493,474 shares of the company's stock after selling 1,893,910 shaNovember 21 at 8:49 AM | marketbeat.comCytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 20 at 4:20 PM | globenewswire.comCytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards ProgramNovember 19 at 5:00 PM | globenewswire.comCautious Hold on Cytek Biosciences Amid Recovery and Growth OpportunitiesNovember 19 at 3:20 PM | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Should You Sell?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Time to Sell?November 19 at 1:34 PM | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Sees Large Decline in Short InterestCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 4,200,000 shares, a decline of 6.0% from the October 15th total of 4,470,000 shares. Approximately 3.6% of the company's shares are sold short. Based on an average daily volume of 673,900 shares, the short-interest ratio is presently 6.2 days.November 18 at 8:46 AM | marketbeat.comCytek Biosciences price target raised to $8.50 from $8 at Piper SandlerNovember 13, 2024 | markets.businessinsider.comPiper Sandler Issues Positive Forecast for Cytek Biosciences (NASDAQ:CTKB) Stock PricePiper Sandler boosted their target price on shares of Cytek Biosciences from $8.00 to $8.50 and gave the stock an "overweight" rating in a report on Monday.November 11, 2024 | marketbeat.comCytek Biosciences introduces ESP Detection Option for Cytek AuroraNovember 7, 2024 | markets.businessinsider.comCytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell SorterNovember 7, 2024 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Stock, Short Interest ReportNovember 7, 2024 | benzinga.comPositive Outlook and Buy Rating for Cytek Biosciences Amid Strong International Performance and Strategic ExpansionNovember 7, 2024 | markets.businessinsider.comCytek Biosciences Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | markets.businessinsider.comCytek Biosciences Inc (CTKB) Q3 2024 Earnings Call Highlights: Revenue Growth and Positive Net ...November 6, 2024 | finance.yahoo.comCytek Biosciences’ Q3 2024 Financial HighlightsNovember 6, 2024 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Up 26.7% Following Strong EarningsCytek Biosciences (NASDAQ:CTKB) Stock Price Up 26.7% on Strong EarningsNovember 6, 2024 | marketbeat.comCytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comPreview: Cytek Biosciences's EarningsNovember 4, 2024 | benzinga.comWhat To Expect From Cytek Biosciences Inc (CTKB) Q3 2024 EarningsNovember 4, 2024 | finance.yahoo.comCytek Biosciences (CTKB) Scheduled to Post Quarterly Earnings on TuesdayCytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Tuesday, November 5, Zacks reports.October 30, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Up 5.4% in SeptemberCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 4,300,000 shares, a growth of 5.4% from the September 15th total of 4,080,000 shares. Currently, 3.6% of the shares of the company are short sold. Based on an average daily trading volume, of 632,100 shares, the days-to-cover ratio is presently 6.8 days.October 17, 2024 | marketbeat.comMillennium Management LLC Raises Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)Millennium Management LLC boosted its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 3,452.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 946,490 shares of the company's stock after purchasing an additional 919,845 shareOctober 12, 2024 | marketbeat.comSquarepoint Ops LLC Purchases 170,539 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)Squarepoint Ops LLC lifted its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 1,013.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 187,361 shares of the company's stock afteOctober 7, 2024 | marketbeat.comRenaissance Technologies LLC Makes New $1.31 Million Investment in Cytek Biosciences, Inc. (NASDAQ:CTKB)Renaissance Technologies LLC acquired a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 233,900 shares of the company's stock, valued at approximately $1,October 6, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comCytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by Algert Global LLCAlgert Global LLC grew its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 133.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 295,275 shares of the company's stock after purchOctober 4, 2024 | marketbeat.comCulture Biosciences Appoints Chris Williams as Chief Executive OfficerSeptember 27, 2024 | tmcnet.comDeerfield Management Company L.P. Series C Acquires Shares of 155,759 Cytek Biosciences, Inc. (NASDAQ:CTKB)Deerfield Management Company L.P. Series C acquired a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 155,759 shares of the company's stock,September 27, 2024 | marketbeat.comCytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and EuropeSeptember 18, 2024 | globenewswire.comCytek Biosciences, Inc.'s (NASDAQ:CTKB) Intrinsic Value Is Potentially 99% Above Its Share PriceSeptember 18, 2024 | finance.yahoo.comCytek Biosciences (NASDAQ:CTKB) Trading 5.5% Higher Cytek Biosciences (NASDAQ:CTKB) Stock Price Up 5.5%September 17, 2024 | marketbeat.comCytek Biosciences COO Chris Williams To ResignSeptember 13, 2024 | markets.businessinsider.comCytek Announces Resignation of Chief Operating Officer Chris WilliamsSeptember 12, 2024 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Stock Price Down 3.8%Cytek Biosciences (NASDAQ:CTKB) Shares Down 3.8%September 12, 2024 | marketbeat.comShort Interest in Cytek Biosciences, Inc. (NASDAQ:CTKB) Declines By 16.3%Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the target of a large decrease in short interest in August. As of August 15th, there was short interest totalling 4,580,000 shares, a decrease of 16.3% from the July 31st total of 5,470,000 shares. Based on an average trading volume of 655,600 shares, the days-to-cover ratio is currently 7.0 days. Approximately 3.8% of the shares of the stock are short sold.September 3, 2024 | marketbeat.comCytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing FacilityAugust 21, 2024 | globenewswire.comCytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest UpdateCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 5,470,000 shares, a decrease of 13.7% from the July 15th total of 6,340,000 shares. Based on an average trading volume of 682,800 shares, the days-to-cover ratio is presently 8.0 days. Approximately 4.6% of the shares of the stock are sold short.August 17, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Price Target Cut to $8.00Piper Sandler reduced their price target on shares of Cytek Biosciences from $8.50 to $8.00 and set an "overweight" rating for the company in a research report on Tuesday.August 13, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Trading Up 3.4%Cytek Biosciences (NASDAQ:CTKB) Shares Up 3.4%August 12, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Misses Estimates By $0.05 EPSCytek Biosciences (NASDAQ:CTKB - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.05). Cytek Biosciences had a negative return on equity of 1.78% and a negative net margin of 5.73%. The firm had revenue of $46.62 million for the quarter, compared to analyst estimates of $49.02 million. During the same period last year, the company earned ($0.02) EPS.August 9, 2024 | marketbeat.comCytek Biosciences: Poised for Turnaround Despite Q2 Setbacks, Analyst Maintains Buy RatingAugust 7, 2024 | markets.businessinsider.comCytek Biosciences Reports Second Quarter 2024 Financial ResultsAugust 6, 2024 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Trading Down 4.8%Cytek Biosciences (NASDAQ:CTKB) Stock Price Down 4.8%August 6, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. boosted its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 1.0% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 12,012,805 shares of the company's stock after acquiring an additional 122,105 sharAugust 6, 2024 | marketbeat.comCytek Biosciences, earnings: here's what to expectAugust 5, 2024 | markets.businessinsider.comCytek Biosciences (CTKB) Set to Announce Quarterly Earnings on TuesdayCytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Tuesday, August 6, Zacks reports.July 31, 2024 | marketbeat.comCytek® Biosciences Automates Panel Design with New Intelligent AlgorithmJuly 30, 2024 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Shares Down 5.1% Cytek Biosciences (NASDAQ:CTKB) Shares Down 5.1%July 29, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) is a favorite amongst institutional investors who own 51%July 22, 2024 | finance.yahoo.comVanguard Group Inc. Purchases 811,279 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)Vanguard Group Inc. increased its position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 7.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,890,700 shares of the company'July 7, 2024 | marketbeat.com Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report... The Next SpaceX Pre-IPO CTKB Media Mentions By Week CTKB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTKB News Sentiment▼0.650.46▲Average Medical News Sentiment CTKB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTKB Articles This Week▼72▲CTKB Articles Average Week Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prothena News Transcat News EyePoint Pharmaceuticals News Standard BioTools News Allogene Therapeutics News Quanterix News Valneva News Aehr Test Systems News Nautilus Biotechnology News Myriad Genetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTKB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTKB Stock Alerts